Xtandi licensed for pre-chemotherapy use

The oral androgen receptor antagonist Xtandi (enzalutamide) is now licensed for metastatic castration-resistant prostate cancer in men who are asymptomatic or mildly symptomatic and in whom chemotherapy is not yet indicated.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more